Becton, Dickinson and Company (BDX)

Becton, Dickinson and Company (NYSE: BDX), commonly known as BD, is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. Led by CEO Tom Polen, the company’s mission is to help people live healthy lives through innovative med-tech solutions. BD envisions a future as the world’s most automated and digitally connected healthcare provider. Holding a dominant position in medical supplies, lab equipment, and patient monitoring, BDX stock is an essential pillar of the global healthcare infrastructure and a member of the "Dividend Aristocrats."

The business operations of BD in late 2025 are defined by its "BD2025" strategy, which focuses on accelerating growth in higher-margin categories like pharmacy automation and molecular diagnostics. In December 2025, BDX stock investors cheered the successful integration of Edwards Lifesciences’ Critical Care business, which has transformed BD into a leader in AI-powered patient monitoring. The company’s core products—including BD Alaris infusion pumps, Vacutainer blood collection tubes, and Pyxis medication management systems—are used in nearly every hospital in the world. The future business strategy for BDX stock involves expanding its "At-Home" diagnostic portfolio and leveraging AI to optimize hospital workflows. Throughout 2025, the company reported record revenue and significant margin expansion, benefiting from the global recovery in surgical procedures. As healthcare systems seek to reduce costs through automation, the specialized technological platforms provided by BDX stock have become mission-critical, supporting the long-term growth case for the stock.

Becton, Dickinson and Company stock is listed on the New York Stock Exchange under the ticker symbol BDX. In late 2025, the BDX stock price has shown a steady climb, recently trading near $255 as the market rewards its consistent earnings beats and strategic portfolio reshaping. Analysts monitoring the BDX stock price highlight the company’s low-volatility profile and its status as a 54-year "Dividend Aristocrat." For those tracking the BDX stock price today, the key catalysts include the rollout of its next-gen infusion platforms and the growth of its biosciences segment. As a titan of the med-tech industry, BDX stock remains a premier selection for stability-seeking investors. The steady performance of the BDX stock price reflects its role as a bedrock of global medicine.